Peter Bradding

List of Publications by Year
in descending order

129 papers	14,750 citations	30070 54 h-index	18647 119 g-index
130 all docs	130 docs citations	130 times ranked	11045 citing authors

#	Article	IF	Citations
1	Mechanisms of Mast Cell Activation in Severe Asthma: Beyond IgE. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 375-377.	5.6	2
2	Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarkerâ€high and â€low severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2974-2986.	5.7	11
3	Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3362-3376.	5.7	7
4	Clinical Outcomes in People with Difficult-to-Control Asthma Using Electronic Monitoring to Support Medication Adherence. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1529-1538.e2.	3.8	20
5	Composite type-2 biomarker strategy versus a symptomâ€"risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 57-68.	10.7	88
6	Potential Role of Mast Cells in Regulating Corticosteroid Insensitivity in Severe Asthma. Advances in Experimental Medicine and Biology, 2021, 1303, 1-12.	1.6	4
7	TGFÎ²1 induces resistance of human lung myofibroblasts to cell death via downâ€regulation of TRPA1 channels. British Journal of Pharmacology, 2021, 178, 2948-2962.	5.4	8
8	Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment. Breathe, 2021, 17, 210024.	1.3	2
9	Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 9960-9988.	6.4	26
10	Mast-Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 431-444.	5.6	11
11	Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 731-734.	5.6	40
12	Human Lung Mast Cells Impair Corticosteroid Responsiveness in Human Airway Smooth Muscle Cells. Frontiers in Allergy, 2021, 2, 785100.	2.8	1
13	Ca2+signalling in fibroblasts and the therapeutic potential of KCa3.1 channel blockers in fibrotic diseases. British Journal of Pharmacology, 2020, 177, 1003-1024.	5.4	23
14	A randomized, placeboâ€controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). Clinical and Experimental Allergy, 2020, 50, 1342-1351.	2.9	30
15	A Feasibility Study of a Randomized Controlled Trial of Asthma-Tailored Pulmonary Rehabilitation Compared with Usual Care in Adults with Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3418-3427.	3.8	16
16	Novel airway smooth muscleâ€"mast cell interactions and a role for the TRPV4-ATP axis in non-atopic asthma. European Respiratory Journal, 2020, 56, 1901458.	6.7	34
17	A comparison of daily physical activity profiles between adults with severe asthma and healthy controls. European Respiratory Journal, 2020, 56, 1902219.	6.7	18
18	ACE2, TMPRSS2, and furin gene expression in the airways of people with asthmaâ€"implications for COVID-19. Journal of Allergy and Clinical Immunology, 2020, 146, 208-211.	2.9	77

#	Article	IF	Citations
19	A Randomized, Placeboâ€Controlled Trial Evaluating Effects of Lebrikizumab on Airway Eosinophilic Inflammation and Remodeling in Uncontrolled Asthma (CLAVIER). FASEB Journal, 2020, 34, 1-1.	0.5	0
20	Patient Perceptions of Living with Severe Asthma: Challenges to Effective Management. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2613-2621.e1.	3.8	21
21	Understanding the measurement properties of the incremental shuttle walk test in patients with severe asthma. Respirology, 2019, 24, 752-757.	2.3	9
22	Tensin1 expression and function in chronic obstructive pulmonary disease. Scientific Reports, 2019, 9, 18942.	3.3	9
23	Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 454-464.	5.6	115
24	Nocturnal temperature-controlled laminar airflow device for adults with severe allergic asthma: the LASER RCT. Health Technology Assessment, 2019, 23, 1-140.	2.8	7
25	The controversial role of mast cells in fibrosis. Immunological Reviews, 2018, 282, 198-231.	6.0	93
26	A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis. Scientific Reports, 2018, 8, 342.	3.3	34
27	Airway pathological heterogeneity in asthma: Visualization of disease microclusters using topological data analysis. Journal of Allergy and Clinical Immunology, 2018, 142, 1457-1468.	2.9	27
28	Exacerbations of severe asthma in patients treated with mepolizumab. European Respiratory Journal, 2018, 52, 1801127.	6.7	16
29	Study of Endogenous CRAC Channels in Human Mast Cells Using an Adenoviral Delivery System to Transduce Cells with Orai-Targeting shRNAs or with cDNAs Expressing Dominant-Negative Orai Channel Mutations. Methods in Molecular Biology, 2018, 1843, 115-124.	0.9	0
30	Inhibition of the K_{Ca}3.1 Channel Alleviates Established Pulmonary Fibrosis in a Large Animal Model. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 539-550.	2.9	26
31	The relationship between the Leicester cough questionnaire, eosinophilic airway inflammation and asthma patient related outcomes in severe adult asthma. Respiratory Research, 2017, 18, 44.	3.6	16
32	Associations in asthma between quantitative computed tomography andÂbronchial biopsy-derived airway remodelling. European Respiratory Journal, 2017, 49, 1601507.	6.7	32
33	A CEACAM6-High Airway Neutrophil Phenotype and CEACAM6-High Epithelial Cells Are Features of Severe Asthma. Journal of Immunology, 2017, 198, 3307-3317.	0.8	31
34	MUC5AC and a Glycosylated Variant of MUC5B Alter Mucin Composition in Children With Acute Asthma. Chest, 2017, 152, 771-779.	0.8	70
35	Î²2-Adrenoceptor Function in Asthma. Advances in Immunology, 2017, 136, 1-28.	2.2	19
36	Endothelial protein C receptor is overexpressed in colorectal cancer as a result of amplification and hypomethylation of chromosome 20q. Journal of Pathology: Clinical Research, 2017, 3, 155-170.	3.0	7

#	Article	IF	Citations
37	Accurately measuring and modeling Th2 and Th17 endotypes in severe asthma. Annals of Translational Medicine, 2017, 5, 91-91.	1.7	7
38	Protocol for a feasibility study to inform the development of a multicentre randomised controlled trial of asthma-tailored pulmonary rehabilitation versus usual care for individuals with severe asthma. BMJ Open, 2016, 6, e010574.	1.9	7
39	Impaired P2X1 Receptorâ€“Mediated Adhesion in Eosinophils from Asthmatic Patients. Journal of Immunology, 2016, 196, 4877-4884.	0.8	13
40	Mast cells in asthma â€“ state of the art. Clinical and Experimental Allergy, 2016, 46, 194-263.	2.9	116
41	P090 <break /> A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis. QJM - Monthly Journal of the Association of Physicians, 2016, , .	0.5	0
42	Reduced epithelial suppressor of cytokine signalling 1 in severe eosinophilic asthma. European Respiratory Journal, 2016, 48, 715-725.	6.7	24
43	New Developments in Mast Cell Biology. Chest, 2016, 150, 680-693.	0.8	35
44	Mast cells in airway diseases and interstitial lung disease. European Journal of Pharmacology, 2016, 778, 125-138.	3.5	54
45	Mast cells and their activation in lung disease. Translational Research, 2016, 174, 60-76.	5.0	61
46	Bidirectional Counterregulation of Human Lung Mast Cell and Airway Smooth Muscle Î²2 Adrenoceptors. Journal of Immunology, 2016, 196, 55-63.	0.8	27
47	Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax, 2016, 71, 187-189.	5.6	78
48	The FcÎµRIÎ² Homologue, MS4A4, Promotes FcÎµRI-Dependent Human Mast Cell Degranulation By Facilitating PLCÎ³1 Signaling. Journal of Allergy and Clinical Immunology, 2015, 135, AB240.	2.9	1
49	Evidence for a novel Kit adhesion domain mediating human mast cell adhesion to structural airway cells. Respiratory Research, 2015, 16, 86.	3.6	6
50	Orai/CRACM1 and KCa3.1 ion channels interact in the human lung mast cell plasma membrane. Cell Communication and Signaling, 2015, 13, 32.	6.5	23
51	KCa3.1 K+ Channel Expression and Function in Human Bronchial Epithelial Cells. PLoS ONE, 2015, 10, e0145259.	2.5	17
52	The CD20 homologue MS4A4 directs trafficking of KIT toward clathrin-independent endocytosis pathways and thus regulates receptor signaling and recycling. Molecular Biology of the Cell, 2015, 26, 1711-1727.	2.1	35
53	Human lung myofibroblast TGFÎ²1-dependent Smad2/3 signalling is Ca2+-dependent and regulated by KCa3.1 K+ channels. Fibrogenesis and Tissue Repair, 2015, 8, 5.	3.4	40
54	T _H 2 and T _H 17 inflammatory pathways are reciprocally regulated in asthma. Science Translational Medicine, 2015, 7, 301ra129.	12.4	380

#	Article	IF	Citations
55	Lipoxin A4 Attenuates Constitutive and TGF-Î²1â€“Dependent Profibrotic Activity in Human Lung Myofibroblasts. Journal of Immunology, 2015, 195, 2852-2860.	0.8	38
56	CADM1 Controls Actin Cytoskeleton Assembly and Regulates Extracellular Matrix Adhesion in Human Mast Cells. PLoS ONE, 2014, 9, e85980.	2.5	27
57	Increased constitutive Î±SMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent. Respiratory Research, 2014, 15, 155.	3.6	44
58	Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: AÂ12-month follow-up analysis. Journal of Allergy and Clinical Immunology, 2014, 133, 921-923.	2.9	150
59	Increased expression of bronchial epithelial transient receptor potential vanilloid 1 channels in patients with severe asthma. Journal of Allergy and Clinical Immunology, 2014, 133, 704-712.e4.	2.9	139
60	Effectiveness of voriconazole in the treatment of Aspergillus fumigatusâ€“associated asthma (EVITA3) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.9	74
61	A Truncated Splice-Variant of the FcÎµRIÎ² Receptor Subunit Is Critical for Microtubule Formation and Degranulation in Mast Cells. Immunity, 2013, 38, 906-917.	14.3	43
62	Functional KCa3.1 Channels Regulate Steroid Insensitivity in Bronchial Smooth Muscle Cells. Journal of Immunology, 2013, 191, 2624-2636.	0.8	31
63	Elevated Sputum Interleukin-5 and Submucosal Eosinophilia in Obese Individuals with Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 657-663.	5.6	198
64	CADM1 is expressed as multiple alternatively spliced functional and dysfunctional isoforms in human mast cells. Molecular Immunology, 2013, 53, 345-354.	2.2	18
65	Ca²⁺-Activated K⁺ Channelâ€“3.1 Blocker TRAM-34 Attenuates Airway Remodeling and Eosinophilia in a Murine Asthma Model. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 212-219.	2.9	30
66	The Contribution of Orai(CRACM)1 and Orai(CRACM)2 Channels in Store-Operated Ca2+ Entry and Mediator Release in Human Lung Mast Cells. PLoS ONE, 2013, 8, e74895.	2.5	25
67	The K+ Channel KCa3.1 as a Novel Target for Idiopathic Pulmonary Fibrosis. PLoS ONE, 2013, 8, e85244.	2.5	43
68	CADM1 Is a Key Receptor Mediating Human Mast Cell Adhesion to Human Lung Fibroblasts and Airway Smooth Muscle Cells. PLoS ONE, 2013, 8, e61579.	2.5	30
69	KCa3.1 Channel-Blockade Attenuates Airway Pathophysiology in a Sheep Model of Chronic Asthma. PLoS ONE, 2013, 8, e66886.	2.5	28
70	The relationship between clinical outcomes and medication adherence in difficult-to-control asthma: Table 1. Thorax, 2012, 67, 751-753.	5.6	259
71	Inflammatory and Satellite Cells in the Quadriceps of Patients With COPD and Response to Resistance Training. Chest, 2012, 142, 1134-1142.	0.8	44
72	Glucocorticoid receptor Î² and histone deacetylase 1 and 2 expression in the airways of severe asthma. Thorax, 2012, 67, 392-398.	5.6	60

#	Article	IF	Citations
73	Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. Journal of Allergy and Clinical Immunology, 2012, 129, 104-111.e9.	2.9	256
74	CRACM/Orai ion channel expression and function in human lung mast cells. Journal of Allergy and Clinical Immunology, 2012, 129, 1628-1635.e2.	2.9	64
75	Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. Journal of Allergy and Clinical Immunology, 2012, 130, 647-654.e10.	2.9	546
76	Primary Human Airway Epithelial Cell-Dependent Inhibition of Human Lung Mast Cell Degranulation. PLoS ONE, 2012, 7, e43545.	2.5	37
77	CADM1 isoforms differentially regulate human mast cell survival and homotypic adhesion. Cellular and Molecular Life Sciences, 2012, 69, 2751-2764.	5.4	20
78	Functional KCa3.1 K+ channels are required for human fibrocyte migration. Journal of Allergy and Clinical Immunology, 2011, 128, 1303-1309.e2.	2.9	33
79	Mast Cells in Lung Inflammation. Advances in Experimental Medicine and Biology, 2011, 716, 235-269.	1.6	33
80	Subclinical phenotypes of asthma. Current Opinion in Allergy and Clinical Immunology, 2010, 10, 54-59.	2.3	37
81	Human Lung Mast Cells Mediate Pneumococcal Cell Death in Response to Activation by Pneumolysin. Journal of Immunology, 2010, 184, 7108-7115.	0.8	46
82	A novel FcÎµRIÎ²â€chain truncation regulates human mast cell proliferation and survival. FASEB Journal, 2010, 24, 4047-4057.	0.5	34
83	Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes. Thorax, 2010, 65, 775-781.	5.6	93
84	Counterregulation of Î²2-adrenoceptor function in human mast cells by stem cell factor. Journal of Allergy and Clinical Immunology, 2010, 125, 257-263.e5.	2.9	22
85	Activation of human mast cells through the platelet-activating factor receptor. Journal of Allergy and Clinical Immunology, 2010, 125, 1137-1145.e6.	2.9	129
86	IgE Sensitization to<i>Aspergillus fumigatus</i>Is Associated with Reduced Lung Function in Asthma. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1362-1368.	5.6	222
87	Qualitative Analysis of High-Resolution CT Scans in Severe Asthma. Chest, 2009, 136, 1521-1528.	0.8	190
88	The K⁺ channels K_{Ca}3.1 and K_v1.3 as novel targets for asthma therapy. British Journal of Pharmacology, 2009, 157, 1330-1339.	5.4	67
89	Fibrocyte localization to the airway smooth muscle is a feature of asthma. Journal of Allergy and Clinical Immunology, 2009, 123, 376-384.	2.9	120
90	Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. New England Journal of Medicine, 2009, 360, 973-984.	27.0	1,672

#	Article	IF	Citations
91	Engagement of the EP₂ prostanoid receptor closes the K⁺ channel K_{Ca}3.1 in human lung mast cells and attenuates their migration. European Journal of Immunology, 2008, 38, 2548-2556.	2.9	40
92	IgE alone promotes human lung mast cell survival through the autocrine production of IL-6. BMC Immunology, 2008, 9, 2.	2.2	43
93	Increased sputum and bronchial biopsy IL-13 expression in severe asthma. Journal of Allergy and Clinical Immunology, 2008, 121, 685-691.	2.9	243
94	Airway hyperresponsiveness is dissociated from airway wall structural remodeling. Journal of Allergy and Clinical Immunology, 2008, 122, 335-341.e3.	2.9	110
95	CCL11 and GM-CSF Differentially Use the Rho GTPase Pathway to Regulate Motility of Human Eosinophils in a Three-Dimensional Microenvironment. Journal of Immunology, 2008, 180, 8354-8360.	0.8	26
96	Human Airway Smooth Muscle Promotes Human Lung Mast Cell Survival, Proliferation, and Constitutive Activation: Cooperative Roles for CADM1, Stem Cell Factor, and IL-6. Journal of Immunology, 2008, 181, 2772-2780.	0.8	100
97	Mast Cells Promote Airway Smooth Muscle Cell Differentiation via Autocrine Up-Regulation of TGF-Î²1. Journal of Immunology, 2008, 181, 5001-5007.	0.8	113
98	Functional Transient Receptor Potential Melastatin 7 Channels Are Critical for Human Mast Cell Survival. Journal of Immunology, 2007, 179, 4045-4052.	0.8	78
99	KCa3.1 Ca2+Activated K+Channels Regulate Human Airway Smooth Muscle Proliferation. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 525-531.	2.9	69
100	Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax, 2007, 62, 1043-1049.	5.6	396
101	The reclassification of asthma based on subphenotypes. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 43-50.	2.3	85
102	Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis. Journal of Allergy and Clinical Immunology, 2007, 120, 813-819.	2.9	87
103	Adenosine closes the K+ channel KCa3.1 in human lung mast cells and inhibits their migrationvia the adenosine A2A receptor. European Journal of Immunology, 2007, 37, 1653-1662.	2.9	53
104	Evidence of a Role of Tumor Necrosis Factor Î± in Refractory Asthma. New England Journal of Medicine, 2006, 354, 697-708.	27.0	783
105	Cooperative molecular and cellular networks regulate Tollâ€like receptorâ€dependent inflammatory responses. FASEB Journal, 2006, 20, 2153-2155.	0.5	76
106	The role of the mast cell in the pathophysiology of asthma. Journal of Allergy and Clinical Immunology, 2006, 117, 1277-1284.	2.9	477
107	Airway Smooth Muscle and Mast Cellâ€"derived CC Chemokine Ligand 19 Mediate Airway Smooth Muscle Migration in Asthma. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1179-1188.	5.6	134
108	Human Lung Mast Cells Adhere to Human Airway Smooth Muscle, in Part, via Tumor Suppressor in Lung Cancer-1. Journal of Immunology, 2006, 176, 1238-1243.	0.8	65

#	Article	IF	Citations
109	Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 572, 1-13.	1.0	25
110	Macrophage and Mast-Cell Invasion of Tumor Cell Islets Confers a Marked Survival Advantage in Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 8959-8967.	1.6	330
111	Mast Cell Ion Channels. , 2005, 87, 163-178.		32
112	Î² 2 â€Adrenoceptor regulation of the K + channel iK Ca 1 in human mast cells. FASEB Journal, 2005, 19, 1006-1008.	0.5	52
113	Differential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration. Journal of Leukocyte Biology, 2005, 77, 759-766.	3.3	84
114	The CXCL10/CXCR3 Axis Mediates Human Lung Mast Cell Migration to Asthmatic Airway Smooth Muscle. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1103-1108.	5.6	264
115	Induced Sputum Inflammatory Mediator Concentrations in Chronic Cough. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 15-19.	5.6	173
116	The K+ channel iKCA1 potentiates Ca2+ influx and degranulation in human lung mast cells. Journal of Allergy and Clinical Immunology, 2004, 114, 66-72.	2.9	101
117	Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. Journal of Allergy and Clinical Immunology, 2004, 114, 1106-1109.	2.9	151
118	Inhibition of human mast cell proliferation and survival by tamoxifen in association with ion channel modulation. Journal of Allergy and Clinical Immunology, 2003, 112, 965-972.	2.9	54
119	Ion channel gene expression in human lung, skin, and cord blood-derived mast cells. Journal of Leukocyte Biology, 2003, 73, 614-620.	3.3	71
120	The role of the mast cell in asthma: a reassessment. Current Opinion in Allergy and Clinical Immunology, 2003, 3, 45-50.	2.3	75
121	Clinical, Radiologic, and Induced Sputum Features of Chronic Obstructive Pulmonary Disease in Nonsmokers. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1078-1083.	5.6	148
122	TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. Journal of Allergy and Clinical Immunology, 2002, 110, 899-905.	2.9	207
123	Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet, The, 2002, 360, 1715-1721.	13.7	1,598
124	Mast-Cell Infiltration of Airway Smooth Muscle in Asthma. New England Journal of Medicine, 2002, 346, 1699-1705.	27.0	1,147
125	Resting and Activation-Dependent Ion Channels in Human Mast Cells. Journal of Immunology, 2001, 167, 4261-4270.	0.8	71
126	Induced Sputum Inflammatory Mediator Concentrations in Eosinophilic Bronchitis and Asthma. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 878-882.	5.6	147

#	Article	IF	Citations
127	Immunopathology and human mast cell cytokines. Critical Reviews in Oncology/Hematology, 1999, 31, 119-133.	4.4	117
128	Human mast cells express stem cell factor. , 1998, 186, 59-66.		104
129	The Mast Cell as a Source of Cytokines in Asthma. Annals of the New York Academy of Sciences, 1996, 796, 272-281.	3.8	41